## Abstract Hepatitis C Virus (HCV) is classified into six genotypes. Genotype 4 is now spreading in Europe, especially among drug users, who are often infected with both HCV and the human immunodeficiency virus (HIV). Previous studies have shown that HCVβ4 responds poorly to interferon. Pegylated
Chronic genotype 4 hepatitis C
β Scribed by Daniel F. Schafer
- Book ID
- 102239398
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 63 KB
- Volume
- 47
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
β¦ Synopsis
My colleagues and I read with great interest the article by Livraghi et al., where the authors stated that radiofrequency ablation (RFA) could be considered the treatment of choice for patients with a singe hepatocellular carcinoma Υ 2 cm, even when surgical treatment is possible. 1 We agree with the main conclusion of the authors. As the authors have pointed out, RFA seems to be equivalent to surgery in terms of local disease control and survival. 1 In addition, RFA is generally much less invasive than surgery and is associated with a lower complication rate. 2 It is no longer unusual that RFA can be the treatment of choice for patients with a single small hepatocellular carcinoma nodule. The investigators must be congratulated for their difficult work.
However, we have a question concerning the statistical analysis. In the study, multivariate analysis demonstrated that the appearance of one or more new lesions was the only statistically significant factor. However, the appearance of any new lesion is a delayed phenomenon after RFA. We think that prognosis prediction based on a delayed phenomenon would be of little value in treatment planning and survival prediction at the initial stage of interventional management. We would like to know the results of multivariate analysis after exclusion of this factor. After the exclusion, other factors such as operability might become statistically significant as determined by multivariate analysis.
π SIMILAR VOLUMES
## Abstract The safety and efficacy of pegylated interferon (PEGβIFN) alfaβ2a and ribavirin were studied among patients treated for genotype 4 chronic hepatitis C. Ninetyβfive patients with chronic hepatitis C genotype 4 were treated with PEGβIFN alfaβ2a (180βΒ΅g/week) plus ribavirin (β₯11βmg/kg/day)